Tango Therapeutics, Inc.

Stage 3 · Topping · week 8

As of Oct 22, 2026, Tango Therapeutics is in Stage 3, the topping phase, now in week 8 (since Sep 1, 2026). It closed at $27.93, 15.1% below its 52-week high and above its 200-day average, which is rising.

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. More about the company

$27.93

+4.03% today

$4.7B · Mid cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is TNGX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 34w

S2 59w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 4w → S2 12w → S3 4w → S2 12w → S3 5w → S4 8w → S1 8w → S2 6w → S3 1w → S4 34w → S1 5w → S2 59w → S3 7w current

Total tracked: 165 weeks across 13 stage runs.

TNGX among Biotechnology21st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…21	TNGXTango Therapeutics, Inc.	Stage 3 · wk 8	98	+14.2%

vs 52W High

-15.1%

$7.50 lo$32.90 hi

15.1% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 8

1w13w26w

Week 8, distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

27.0%

200 DMA: $21.99 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

1.97x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↗

Short-term trend rising gently

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+14.2%

+4.9%

+8.0%

YTD

+212.8%

+210.7%

Scan Membership

Breakout Watch

Latest: 2024-08-19

6 appearances in last 60 days. First seen: 2021-06-21.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 8 · Vol 1.97x

2026-10-21S3

Wk 8 · Vol 1.73x

2026-10-20S3

Wk 7 · Vol 0.90x

2026-10-19S3

Wk 7 · Vol 0.62x

2026-10-16S3

Wk 7 · Vol 1.25x

2026-10-15S3

Wk 7 · Vol 0.99x

2026-10-14S3

Wk 7 · Vol 1.19x

2026-10-13S3

Wk 6 · Vol 3.51x

2026-10-12S3

Wk 6 · Vol 1.06x

2026-10-09S3

Wk 6 · Vol 1.15x

2026-10-08S3

Wk 6 · Vol 1.93x

2026-10-07S3

Wk 6 · Vol 1.26x

Moving averages & range

50 DMA

$23.90

200 DMA

$21.99

52W High

$32.90

52W Low

$7.50

5D Low

$22.04

Resistance levels (recent highs)

20d High

$27.93

60d High

$29.36

120d High

$32.90

250d High

$32.90

Next resistance

+5.1%

to 60d High

ROE

-21.3%

Profit margin -229.9%

Dividend Yield

0.00%

P/B 4.6

Tango Therapeutics: quick answers

What stage is Tango Therapeutics in?

As of Oct 22, 2026, Tango Therapeutics (TNGX) is in Stage 3, the topping phase. It entered Stage 3 on Sep 1, 2026 and is in week 8. What the four stages mean

Is Tango Therapeutics in an uptrend?

Its uptrend has stalled. Tango Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 27.0% above its 200-day average, which is rising.

How far is Tango Therapeutics from its 52-week high?

Tango Therapeutics closed at $27.93 on Oct 22, 2026, 15.1% below its 52-week high of $32.90. Its 52-week low is $7.50.

How has Tango Therapeutics performed over the past year?

As of Oct 22, 2026, Tango Therapeutics is up 210.7% over the past year and up 212.8% so far in 2026.

Which sector and industry is Tango Therapeutics in?

Tango Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.